Clinical Trial Delays Start Long Before Study Subject Enrollment
When a clinical trial falls behind schedule, enrollment is often the first place sponsors look for answers.
Slow recruitment, site performance issues, and participant retention challenges certainly contribute to delays. However, many of the most significant timeline setbacks occur long before the first patient is screened.
For medical device, combination product, and biotechnology companies, successful trial execution begins during study planning. Decisions made during protocol development, regulatory strategy, site selection, and study startup influence every stage of the trial. When these activities are rushed or approached in isolation, delays can quickly compound and become difficult to correct once enrollment begins.
The good news is that many common clinical trial delays are preventable with the right planning, expertise, and operational strategy.
The Hidden Costs of Poor Clinical Planning
Development teams are often under pressure to demonstrate progress. Investors want milestones. Leadership wants timelines. Product teams want data.
As a result, organizations sometimes focus on accelerating study startup without fully addressing foundational planning activities.
Unfortunately, this approach can create downstream challenges such as:
Protocol amendments after study launch
Additional regulatory questions
Site activation delays
Budget overruns
Enrollment disruptions
Incomplete or unusable data
Delayed regulatory submissions
While these issues may appear during study execution, they often originate from decisions made months earlier during the planning phase.
11 Reasons Clinical Trial Delays Often Begin During Study Startup
1. Protocol Development
The protocol is the blueprint for the entire clinical trial. Every operational activity, data collection requirement, and statistical analysis stems from the protocol.
Poorly designed protocols often result in:
Protocol amendments
Operational inefficiencies
Increased protocol deviations
Delayed enrollment
Additional costs
Investing the time to build a practical, scientifically sound protocol helps reduce downstream delays and creates a stronger foundation for the study.
2. Alignment on Trial Design Between Investigators and Sponsors
Even a well-written protocol can encounter challenges if investigators and sponsors aren’t aligned on study objectives and execution.
Early discussions should establish consensus around:
Study objectives
Follow-up duration
Operational expectations
Patient population
Study procedures
Endpoints
Establishing alignment before activation reduces confusion, improves protocol adherence, and minimizes avoidable amendments later in the study.
3. Vendor Management
Most clinical studies rely on multiple external partners, including laboratories, CRO, EDC provider, biostatistics teams, core laboratories, and logistics providers.
Delays frequently occur when:
Vendor responsibilities are unclear
Timelines aren’t coordinated
Contracts are finalized late
System integrations are incomplete
Early vendor selection and proactive project management help ensure every partner is prepared before enrollment begins.
4. Integrated, Early Planning
Clinical strategy and regulatory strategy should be developed together from the outset.
Regulatory planning influences:
Clinical evidence requirements for desired claims
Safety monitoring
Follow-up duration
Compliance considerations
Submission strategy
When regulatory considerations are introduced late in the process, sponsors may discover that their study design doesn’t fully address regulatory expectations or that the level of compliance (data capture methodology, monitoring, and quality procedures) aren’t adequate to fulfill premarket clinical study requirements.
5. Site Selection and Startup
Site startup involves much more than selecting investigators.
Sponsors must evaluate:
Size of the eligible patient population and enrollment potential
Investigator experience
Competing trials at the site
Site infrastructure (participation of satellite sites, IRB requirements, catchment area and patient geographical spread, location of imaging follow-ups, etc.)
Staff availability and experience
Contracting requirements
Budget negotiations
Training needs
Even highly qualified sites can become bottlenecks if startup activities aren’t managed effectively.
Site qualification, contracting, budget negotiations, IRB timelines, training, and activation represent some of the longest components of study startup. Proactive planning helps reduce these delays and improves study readiness.
6. Underestimating Documentation Requirements
Clinical trial startup requires a substantial amount of documentation before enrollment can begin.
Required documents may include:
Protocol
Case Report Forms (CRFs)
Informed Consent Forms (ICFs)
Investigator Brochure
Monitoring Plan
Statistical Analysis Plan
Data Management Plan
Safety Management Plan
DSMB, CEC, and Core Laboratory Charters
Recruitment Materials
Each document must be developed, reviewed, approved, and maintained under version control.
Organizations can underestimate the necessity of these documents and the time and coordination required to complete these activities, leading to delays that affect study initiation and site activation.
7. Database Development and Documentation
The clinical database should be fully configured and validated before the first participant is enrolled.
Startup activities include:
Database configuration
Edit checks
User Acceptance Testing (UAT)
Validation
User permissions
Reporting requirements
System for MedDRA and WHODrug coding
Completing these activities early supports data quality and minimizes disruptions during enrollment.
8. Failure to Plan for CMS Review Time
For IDE studies that receive CMS Categorization from the FDA, CMS must also review the study prior to initiation if sites are going to bill CMS for clinical activities conducted during the study. Sponsors often neglect to account for CMS review timelines during study planning.
Waiting until IDE approval to prepare the CMS application for coverage can affect study initiation and site budget negotiation timelines.
Planning for both regulatory and reimbursement pathways from the beginning helps avoid unnecessary delays.
9. Integrating Intended Regulatory Claims into Trial Design
Clinical trials should be designed to support the claims a sponsor ultimately intends to make.
That means ensuring:
Clinical endpoints support intended indications
Follow-up periods capture the necessary evidence
Data collection aligns with regulatory expectations
Waiting until submission preparation to evaluate claim support can reveal evidence gaps that are difficult—or impossible—to address retrospectively.
10. Considering the Competitive Product Landscape
Clinical trial design should reflect not only regulatory expectations but also the current standard of care and competing technologies.
Competitive landscape assessments can influence:
Patient population
Comparator selection
Follow-up duration
Primary and secondary endpoints
Understanding how competing products were studied helps sponsors generate evidence that differentiates their technology in the marketplace.
11. Selecting Endpoints That Support Reimbursement
Regulatory approval is only one milestone.
Sponsors should also consider whether their clinical endpoints demonstrate outcomes that matter to:
Payers
Providers
Health systems
Patients
Designing studies with reimbursement and the end user in mind helps generate evidence that supports both market access and long-term commercial success.
Why Integrated Clinical and Regulatory Planning Matters
The strongest clinical trial programs are built around a simple principle: every study activity should support a larger development objective.
Clinical studies are not conducted simply to collect data. They are conducted to answer questions that support regulatory decisions, reimbursement discussions, commercialization strategies, and ultimately patient access.
When clinical and regulatory teams operate independently, sponsors often encounter duplicated efforts, unnecessary testing, and evidence gaps that delay development.
An integrated approach helps organizations:
Design studies that align with regulatory expectations
Generate meaningful clinical evidence
Reduce unnecessary costs
Improve operational efficiency
Support future market access and reimbursement initiatives
By aligning strategy early, companies can avoid many of the challenges that cause delays later.
How NMCG Support Clinical Trial Success
Our team supports sponsors throughout the clinical development lifecycle, including:
Clinical trial strategy
Protocol development
Trial design and endpoint selection
Statistical analyses and power calculations
Regulatory strategy and submission planning
Steering Committee, DSMB, and CEC planning
Vendor selection and management
Site selection and startup
Database development and validation
Data management
Safety oversight
Clinical Study Report (CSR) writing
Reimbursement strategy and evidence planning
Because our clinical and regulatory teams work together throughout the product lifecycle, we help clients generate evidence that supports regulatory submissions, reimbursement objectives, and commercialization while maintaining efficient study execution.
Building Strong Studies Before Enrollment Begins
Clinical trial delays rarely start with enrollment.
More often, they begin during study planning through incomplete preparation, disconnected strategies, or underestimated startup requirements.
Organizations that invest in thoughtful clinical and regulatory planning position themselves for smoother execution, stronger data quality, and more successful development outcomes.
The most effective way to accelerate a clinical trial is often to slow down just enough at the beginning to build the right foundation.
Why It Matters
Clinical trial success is determined long before the first participant is enrolled. Decisions made during protocol development, regulatory planning, governance, operational readiness, and evidence strategy shape the quality of the data, the efficiency of study execution, and the likelihood of regulatory and commercial success.
At NMCG, we help sponsors build integrated clinical development strategies that connect trial design, regulatory objectives, reimbursement planning, and commercialization from the earliest stages of development—reducing risk, minimizing avoidable delays, and generating evidence that supports the entire product lifecycle.
Ready to plan your next clinical study?
Whether you're preparing for a first-in-human study, pivotal trial, post-market study, or
reimbursement-focused clinical program, our team can help you develop a strategy that
supports both your clinical and regulatory goals.
